Artiva Biotherapeutics (NASDAQ:ARTV) COO Jennifer Bush Sells 8,790 Shares

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) COO Jennifer Bush sold 8,790 shares of Artiva Biotherapeutics stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $9.01, for a total value of $79,197.90. Following the completion of the sale, the chief operating officer directly owned 337,920 shares in the company, valued at approximately $3,044,659.20. This represents a 2.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Stock Performance

Shares of Artiva Biotherapeutics stock opened at $8.55 on Wednesday. The business’s 50 day simple moving average is $8.32 and its 200 day simple moving average is $5.65. Artiva Biotherapeutics, Inc. has a 52-week low of $1.47 and a 52-week high of $14.53. The firm has a market cap of $211.36 million, a PE ratio of -2.42 and a beta of 2.86.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). As a group, equities research analysts predict that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ARTV. Prelude Capital Management LLC acquired a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $41,000. Bank of America Corp DE grew its holdings in Artiva Biotherapeutics by 225.8% in the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after buying an additional 11,190 shares in the last quarter. Bridgeway Capital Management LLC acquired a new position in Artiva Biotherapeutics in the 2nd quarter valued at $53,000. Qube Research & Technologies Ltd acquired a new position in Artiva Biotherapeutics in the 2nd quarter valued at $58,000. Finally, Jane Street Group LLC acquired a new position in Artiva Biotherapeutics in the 2nd quarter valued at $67,000.

Analyst Ratings Changes

ARTV has been the topic of a number of analyst reports. Wall Street Zen cut Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. Wedbush upped their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Needham & Company LLC upped their price objective on Artiva Biotherapeutics from $18.00 to $41.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Finally, Cantor Fitzgerald upped their price objective on Artiva Biotherapeutics from $10.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.